Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Degenerative Disc Disease-Pipeline Review, H1 2015

Degenerative Disc Disease-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Degenerative Disc Disease-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Degenerative Disc Disease-Pipeline Review, H1 2015', provides an overview of the Degenerative Disc Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Degenerative Disc Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Degenerative Disc Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Degenerative Disc Disease and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Degenerative Disc Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Degenerative Disc Disease pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Degenerative Disc Disease

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Degenerative Disc Disease pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Degenerative Disc Disease Overview 8

Therapeutics Development 9

Pipeline Products for Degenerative Disc Disease-Overview 9

Pipeline Products for Degenerative Disc Disease-Comparative Analysis 10

Degenerative Disc Disease-Therapeutics under Development by Companies 11

Degenerative Disc Disease-Therapeutics under Investigation by Universities/Institutes 13

Degenerative Disc Disease-Pipeline Products Glance 14

Clinical Stage Products 14

Early Stage Products 15

Unknown Stage Products 16

Degenerative Disc Disease-Products under Development by Companies 17

Degenerative Disc Disease-Products under Investigation by Universities/Institutes 18

Degenerative Disc Disease-Companies Involved in Therapeutics Development 19

AnGes MG, Inc. 19

Biogenomics Limited 20

Bioheart, Inc. 21

BioRestorative Therapies, Inc. 22

Bone Therapeutics SA 23

DePuy Spine, Inc. 24

Discgenics, Inc 25

ISTO Technologies, Inc. 26

K-Stemcell Co., Ltd. 27

Mesoblast Limited 28

TissueGene, Inc. 29

Yuhan Corporation 30

Degenerative Disc Disease-Therapeutics Assessment 31

Assessment by Monotherapy Products 31

Assessment by Target 32

Assessment by Mechanism of Action 34

Assessment by Route of Administration 36

Assessment by Molecule Type 38

Drug Profiles 40

AdipoCell-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

ALLOB-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

brtxDISC-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

CHND-1-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

dibotermin alfa-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

MPC-25Osteo-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

NuQu Cell-Based Therapy-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Peptides to Antagonize IL-1 Receptor for Dermatology, Musculoskeletal and CNS Disorders-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Poly N-Acetyl Glucosamine Hydrogel-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Recombinant Protein for Degenerative Disc Disease-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

S-414114-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Stem Cell Therapy-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Stem Cell Therapy for Degenerative Disc Disease-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Stem Cell Therapy for Degenerative Disc Disease-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Stem Cell Therapy for Degenerative Disc Disease-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

TG-D-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

YH-14618-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Degenerative Disc Disease-Recent Pipeline Updates 62

Degenerative Disc Disease-Product Development Milestones 67

Featured News & Press Releases 67

Jan 12, 2015: BioRestorative Therapies Reports Successful Meeting with FDA 67

Nov 24, 2014: BioRestorative Therapies Schedules Pre-IND Meeting With FDA 67

Nov 17, 2014: Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease 67

Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB phase II trial in spine fusion 68

Mar 26, 2014: Bioheart Announces Clinical Study for Degenerative Disc Disease 69

Mar 07, 2014: Stem Cell Transplant Shows Landmark Promise for Treatment of Degenerative Disc Disease 69

Appendix 71

Methodology 71

Coverage 71

Secondary Research 71

Primary Research 71

Expert Panel Validation 71

Contact Us 71

Disclaimer 72

List of Tables

Number of Products under Development for Degenerative Disc Disease, H1 2015 9

Number of Products under Development for Degenerative Disc Disease-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Development, H1 2015 15

Comparative Analysis by Unknown Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Investigation by Universities/Institutes, H1 2015 18

Degenerative Disc Disease-Pipeline by AnGes MG, Inc., H1 2015 19

Degenerative Disc Disease-Pipeline by Biogenomics Limited, H1 2015 20

Degenerative Disc Disease-Pipeline by Bioheart, Inc., H1 2015 21

Degenerative Disc Disease-Pipeline by BioRestorative Therapies, Inc., H1 2015 22

Degenerative Disc Disease-Pipeline by Bone Therapeutics SA, H1 2015 23

Degenerative Disc Disease-Pipeline by DePuy Spine, Inc., H1 2015 24

Degenerative Disc Disease-Pipeline by Discgenics, Inc, H1 2015 25

Degenerative Disc Disease-Pipeline by ISTO Technologies, Inc., H1 2015 26

Degenerative Disc Disease-Pipeline by K-Stemcell Co., Ltd., H1 2015 27

Degenerative Disc Disease-Pipeline by Mesoblast Limited, H1 2015 28

Degenerative Disc Disease-Pipeline by TissueGene, Inc., H1 2015 29

Degenerative Disc Disease-Pipeline by Yuhan Corporation, H1 2015 30

Assessment by Monotherapy Products, H1 2015 31

Number of Products by Stage and Target, H1 2015 33

Number of Products by Stage and Mechanism of Action, H1 2015 35

Number of Products by Stage and Route of Administration, H1 2015 37

Number of Products by Stage and Molecule Type, H1 2015 39

Degenerative Disc Disease Therapeutics-Recent Pipeline Updates, H1 2015 62

List of Figures

Number of Products under Development for Degenerative Disc Disease, H1 2015 9

Number of Products under Development for Degenerative Disc Disease-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Clinical Stage Development, H1 2015 14

Comparative Analysis by Early Stage Products, H1 2015 15

Assessment by Monotherapy Products, H1 2015 31

Number of Products by Top 10 Targets, H1 2015 32

Number of Products by Stage and Top 10 Targets, H1 2015 33

Number of Products by Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 35

Number of Products by Top 10 Routes of Administration, H1 2015 36

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 37

Number of Products by Top 10 Molecule Types, H1 2015 38

Number of Products by Stage and Top 10 Molecule Types, H1 2015 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AnGes MG, Inc.

Biogenomics Limited

Bioheart, Inc.

BioRestorative Therapies, Inc.

Bone Therapeutics SA

DePuy Spine, Inc.

Discgenics, Inc

ISTO Technologies, Inc.

K-Stemcell Co., Ltd.

Mesoblast Limited

TissueGene, Inc.

Yuhan Corporation

Degenerative Disc Disease Therapeutic Products under Development, Key Players in Degenerative Disc Disease Therapeutics, Degenerative Disc Disease Pipeline Overview, Degenerative Disc Disease Pipeline, Degenerative Disc Disease Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com